Bionomics Limited
BNOEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | -$0 | $0 | $0 |
| % Growth | 100% | -165.6% | 2,130.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | $0 |
| % Margin | – | 97.9% | 98.9% | 0% |
| R&D Expenses | $0 | $9 | $0 | $0 |
| G&A Expenses | $0 | $8 | $0 | $0 |
| SG&A Expenses | $0 | $8 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $17 | $0 | $0 |
| Operating Income | -$0 | -$1 | $0 | -$0 |
| % Margin | – | 7,238.8% | 79.8% | -558.8% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$1 | $0 | -$0 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | 2,414.3% | 75.1% | -293.2% |
| EPS | -4.41 | -6.77 | 6.55 | -0.008 |
| % Growth | 34.9% | -203.4% | 79,015.7% | – |
| EPS Diluted | -4.41 | -6.77 | 6.55 | -0.008 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$0 | -$1 | $0 | -$0 |
| % Margin | – | 5,406.5% | 75.6% | -291.5% |